Table 4.
ZIKV vaccine candidates in clinical testing as of January 2020 (clinicaltrials.gov)
| Title | Status | Interventions | Sponsor/Collaborators | Age Range (yrs) | Phase | Sample Size | Locations |
|---|---|---|---|---|---|---|---|
| Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study | Completed | Biological: Zika Virus Purified Inactivated Vaccine|Other: Placebo | Kathryn Stephenson|Walter Reed Army Institute of Research (WRAIR)|National Institute of Allergy and Infectious Diseases (NIAID)|Beth Israel Deaconess Medical Center | 18 − 50 | 1 | 36 | US |
| ZIKA Vaccine in Naive Subjects | Completed | Drug: Saline|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV) | National Institute of Allergy and Infectious Diseases (NIAID) | 18 – 49 | 1 | 91 | US |
| Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP | Recruiting | Biological: Two MV-ZIKA-RSP vaccinations (high dose)|Biological: Two MV-ZIKA-RSP vaccination (low dose)|Biological: One MV-ZIKA-RSP vaccination (high dose) and one placebo|Other: Two placebo injection | Themis Bioscience GmbH | 18 – 55 | 1 | 48 | Austria |
| Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults | Completed | Biological: VRC-ZKADNA085-00-VP | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) | 18 – 35 | 1 | 80 | US |
| Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area | Active, not recruiting | Other: Placebo|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV) | National Institute of Allergy and Infectious Diseases (NIAID) | 21 – 49 | 1 | 91 | Puerto Rico |
| Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults | Completed | Biological: rZIKV/D4Δ30-713|Biological: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | 18 – 50 | 1 | 28 | US |
| Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | Recruiting | Biological: mRNA-1893|Other: Placebo | ModernaTX, Inc.|Biomedical Advanced Research and Development Authority | 18 – 49 | 1 | 120 | US Puerto Rico |
| VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults | Completed | Biological: VRC-ZKADNA090-00-VP | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) | 18 – 50 | 1 | 45 | US |
| Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults | Completed | Biological: VLA1601|Biological: Placebo | Valneva Austria GmbH|Emergent BioSolutions | 18 – 49 | 1 | 67 | US |
| Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001) | Recruiting | Biological: ChAdOx1 Zika|Biological: ChAdOx1 Zika, ChAdOx1 Chik | University of Oxford | 18 – 50 | 1 | 57 | UK |
| A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. | Completed | Biological: IXIARO|Other: Placebo|Biological: YF Vax 17D Strain|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV) | National Institute of Allergy and Infectious Diseases (NIAID) | 18 – 49 | 1 | 75 | US |
| Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability | Completed | Biological: MV-ZIKA|Other: Placebo | Themis Bioscience GmbH | 18 – 55 | 1 | 48 | Austria |
| Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants | Active, not recruiting | Drug: Placebo|Biological: PIZV | Takeda | 18 – 49 | 1 | 271 | US Puerto Rico |
| VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents | Completed | Biological: VRC-ZKADNA090-00-VP|Other: VRC-PBSPLA043-00-VP | National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|Leidos Biomedical Research, Inc.|FHI Clinical, Inc.|PPD | 15 – 35 | 2 | 2338 | US Brazil Colombia Costa Rica Ecuador Mexico Panama Peru Puerto Rico |
| Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects | Completed | Biological: mRNA-1325|Other: Placebo | ModernaTX, Inc.|Biomedical Advanced Research and Development Authority | 18 – 49 | 1 | 90 | US |
| Study of GLS-5700 in Dengue Virus Seropositive Adults | Completed | Biological: GLS-5700|Biological: Placebo | GeneOne Life Science, Inc.|Inovio Pharmaceuticals | 18 – 65 | 1 | 160 | US Puerto Rico |
| Study of GLS-5700 in Healthy Volunteers | Completed | Biological: GLS-5700 | GeneOne Life Science, Inc.|Inovio Pharmaceuticals | 18 – 65 | 1 | 40 | US Canada |